2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersEsophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani J, D'Amico T, Bentrem D, Cooke D, Corvera C, Das P, Enzinger P, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter W, Ilson D, Jalal S, Keswani R, Kim S, Kleinberg L, Klempner S, Lacy J, Licciardi F, Ly Q, Matkowskyj K, McNamara M, Miller A, Mukherjee S, Mulcahy M, Outlaw D, Perry K, Pimiento J, Poultsides G, Reznik S, Roses R, Strong V, Su S, Wang H, Wiesner G, Willett C, Yakoub D, Yoon H, McMillian N, Pluchino L. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 393-422. PMID: 37015332, DOI: 10.6004/jnccn.2023.0019.Peer-Reviewed Original ResearchConceptsEsophagogastric junction cancerSquamous cell carcinomaJunction cancerMetastatic diseaseSystemic therapyNCCN Clinical Practice GuidelinesEsophageal squamous cell carcinomaMajor global health problemBest supportive careManagement of recurrentMultidisciplinary team managementClinical practice guidelinesTreatment of patientsGlobal health problemMicrosatellite instability statusNCCN guidelinesPalliative managementSupportive careEsophagogastric junctionCell carcinomaLower esophagusEsophageal cancerHER2 statusTumor locationBiomarker testingAtezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
Ko A, Kim K, Siveke J, Lopez C, Lacy J, O'Reilly E, Macarulla T, Manji G, Lee J, Ajani J, Alsina Maqueda M, Rha S, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh C, Gan X, Cha E, Oh D. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist 2023, 28: 553-e472. PMID: 36940261, PMCID: PMC10243783, DOI: 10.1093/oncolo/oyad022.Peer-Reviewed Original ResearchConceptsObjective response ratePancreatic ductal adenocarcinomaGrade 3/4 adverse eventsGrade 5 adverse eventsAdverse eventsGastric cancerDuctal adenocarcinomaPhase Ib/II trialAdvanced pancreatic ductal adenocarcinomaLimited clinical activitySafety of atezolizumabRecombinant human hyaluronidaseEligible patientsVersus ChemotherapyII trialPrimary endpointRECIST 1.1Early efficacySafety profileAtezolizumabClinical activitySafety signalsPEGPH20Response rateHuman hyaluronidaseEffect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Huffman B, Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M, Beg M, Murphy J, Mavroukakis S, Zaki A, Schlechter B, Sanoff H, Manz C, Wolpin B, Arlen P, Lacy J, Cleary J. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma. JAMA Network Open 2023, 6: e2249720. PMID: 36602796, PMCID: PMC9856813, DOI: 10.1001/jamanetworkopen.2022.49720.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaObjective response rateProgression-free survivalSecond-line treatmentNab-paclitaxelOverall survivalClinical trialsDuctal adenocarcinomaRandomized phase II clinical trialMedian progression-free survivalGemcitabine/nab-paclitaxelCox proportional hazards analysisEnd pointPhase II clinical trialChemotherapy dose reductionsFirst-line FOLFIRINOXSecond-line gemcitabineMedian overall survivalPrimary end pointSecondary end pointsProportional hazards analysisSurvival of patientsLow performance statusPretreatment clinical variables
2022
An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center.
Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center. Archives Of Pathology & Laboratory Medicine 2022, 147: 185-192. PMID: 35512224, DOI: 10.5858/arpa.2021-0457-oa.Peer-Reviewed Original ResearchConceptsLiver biopsyUnknown primaryIHC markersPrimary siteTrue carcinomaTertiary care medical centerAvailable clinicopathologic dataSquamous cell carcinomaClinicopathologic dataHepatic metastasesNonepithelial tumorsCell carcinomaInstitutional databaseClinical managementStain usePractice patternsNeuroendocrine neoplasmsImmunohistochemical markersMedical CenterMorphologic patternsIndividualized approachCarcinomaBiopsyMetastasisTumorsYale Precision Medicine Tumor Board: reawakening the guardian of the genome
Grant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome. The Lancet Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/s1470-2045(22)00037-7.Peer-Reviewed Case Reports and Technical Notes
2017
A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia
Curtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.Peer-Reviewed Original ResearchConceptsDrug-induced immune thrombocytopeniaAutoimmune hemolytic anemiaPlatelet-reactive antibodiesImmune thrombocytopeniaThrombotic microangiopathyAdministration of oxaliplatinCycles of FOLFOXOxaliplatin-induced thrombocytopeniaYear old manAnti-RBC IgGEvans syndromeAntibody testingFirst admissionIgM antibodiesSignificant thrombocytopeniaIgG antibodiesHemolytic anemiaThrombocytopeniaLeucovorinPlatelet IgGOlder menOxaliplatinSyndromeBlood centersPatients
2000
Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness M, Kenney J, Reiss M, Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Research 2000, 60: 5354-8. PMID: 11034070.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusPosttransplant lymphoproliferative disorderLymphoproliferative disordersBcl-2 antisenseLymphoproliferative diseaseImmunodeficient miceEpstein-Barr virus-associated lymphoproliferative diseaseBcl-2EBV-positive lymphoproliferative diseaseSequence-dependent antitumor effectsMajority of EBVAntisense oligodeoxynucleotide therapyEBV-positive malignanciesB-cell lymphoproliferationBcl-2 antisense therapyInhibition of proliferationLymphoblastoid B cellsTreatment strategiesChemoprotective effectsAntitumor effectsVitro treatmentB cellsChimeric modelDecreased expressionRational targetAntisense to the Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) sensitizes EBV‐immortalized B cells to transforming growth factor‐beta and chemotherapeutic agents
Kenney J, Guinness M, Reiss M, Lacy J. Antisense to the Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) sensitizes EBV‐immortalized B cells to transforming growth factor‐beta and chemotherapeutic agents. International Journal Of Cancer 2000, 91: 89-98. PMID: 11149426, DOI: 10.1002/1097-0215(20010101)91:1<89::aid-ijc1015>3.0.co;2-u.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicApoptosisB-LymphocytesCell DivisionCell Line, TransformedCell SeparationCyclin D2CyclinsDexamethasoneDNA, AntisenseDown-RegulationEtoposideFlow CytometryHumansImmunoblottingLymphomaMyeloid Cell Leukemia Sequence 1 ProteinNeoplasm ProteinsProto-Oncogene Proteins c-bcl-2Transforming Growth Factor betaTumor Cells, CulturedVincristineViral Matrix ProteinsConceptsLatent membrane protein 1Epstein-Barr virusLymphoblastoid cell linesLMP-1B cellsMembrane protein 1Antisense oligodeoxynucleotidesEBV-positive lymphoproliferative disordersChemotherapeutic agentsEBV-positive lymphoblastoid cell linesEBV-positive cell linesProtein 1Human B cell growthAntisense treatmentApoptotic effectsRational therapeutic targetShort-term treatmentLMP-1 expressionRational therapeutic strategiesB cell growthCell linesLMP-1 proteinTumor necrosis factor receptor familyInhibition of proliferationLymphoproliferative disorders
1997
Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23.
Shieh B, Schultz J, Guinness M, Lacy J. Regulation of the human IgE receptor (Fc epsilonRII/CD23) by Epstein-Barr virus (EBV): Ku autoantigen binds specifically to an EBV-responsive enhancer of CD23. International Immunology 1997, 9: 1885-1895. PMID: 9466316, DOI: 10.1093/intimm/9.12.1885.Peer-Reviewed Original Research
1996
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E, Cooper D, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Journal Of Clinical Oncology 1996, 14: 1943-9. PMID: 8656264, DOI: 10.1200/jco.1996.14.6.1943.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusMTX withdrawalLymphoproliferative disordersComplete remissionPolymerase chain reactionRheumatic diseasesPartial responseAbsence of EBVNegative Epstein-Barr virusEBV RNA transcriptsSpontaneous complete remissionLow-grade lymphomaCNS involvementExtranodal diseaseImmunosuppressive therapyMethotrexate therapyMTX therapyInitial managementAggressive lymphomaClinicopathologic featuresHodgkin's diseasePathologic findingsRheumatoid arthritisSitu hybridization studiesSpontaneous regression
1994
Regulation of the human IgE receptor (Fc epsilon RII/CD23) by EBV. Localization of an intron EBV-responsive enhancer and characterization of its cognate GC-box binding factors.
Lacy J, Roth G, Shieh B. Regulation of the human IgE receptor (Fc epsilon RII/CD23) by EBV. Localization of an intron EBV-responsive enhancer and characterization of its cognate GC-box binding factors. The Journal Of Immunology 1994, 153: 5537-48. PMID: 7989755, DOI: 10.4049/jimmunol.153.12.5537.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCell LineCell Line, TransformedCell Transformation, ViralChloramphenicol O-AcetyltransferaseDNA-Binding ProteinsElectrophoresisEnhancer Elements, GeneticGene Expression RegulationGenes, ReporterHerpesvirus 4, HumanHumansIntronsMolecular Sequence DataPhosphorylationReceptors, IgETransfectionUltraviolet RaysEpstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells.
Roth G, Curiel T, Lacy J. Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 1994, 84: 582-7. PMID: 8025284, DOI: 10.1182/blood.v84.2.582.bloodjournal842582.Peer-Reviewed Original ResearchConceptsEBNA-1EBNA-1 proteinAntisense oligodeoxynucleotidesEpstein-Barr virus-immortalized B cellsEpstein-Barr virus nuclear antigen 1EBV-negative cellsLatent viral proteinsNuclear antigen 1Potential therapeutic implicationsLymphoblastoid cellsEpisomal viral genomesUnmodified antisense oligodeoxynucleotidesNeoplastic diseaseTherapeutic implicationsB cellsInhibited proliferationEBVEffect of antisenseAntigen 1Antiproliferative effectsProtein expressionUntreated cellsImmortalized cellsViral proteinsProliferation
1992
Transcriptional regulation of the human IgE receptor (Fc epsilon RII/CD23) by EBV. Identification of EBV-responsive regulatory elements in intron 1.
Lacy J, Rudnick H. Transcriptional regulation of the human IgE receptor (Fc epsilon RII/CD23) by EBV. Identification of EBV-responsive regulatory elements in intron 1. The Journal Of Immunology 1992, 148: 1554-60. PMID: 1311350, DOI: 10.4049/jimmunol.148.5.1554.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, Differentiation, B-LymphocyteAntigens, ViralBase SequenceChloramphenicol O-AcetyltransferaseEnhancer Elements, GeneticEpstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanHumansImmunoglobulin EIntronsMolecular Sequence DataReceptors, FcReceptors, IgERNA, MessengerTranscription, GeneticConceptsRegulatory elementsTranscriptional activationSpecific DNA-protein complexesIntron 1DNA-protein complexesMaintenance of immortalizationTranscriptional regulatory elementsMobility shift assaysReporter gene assayNuclear runoff analysisAdjacent flanking regionsTranscriptional regulationLymphoma linesIntron sequencesNuclear proteinsShift assaysFirst intronEnhancer activityHeterologous promoterReporter geneFlanking regionsEnhancer elementsMolecular mechanismsGene assayGenes
1991
Conversion of a human B cell lymphoma line by Epstein-Barr virus is associated with increased tyrosine phosphorylation of a 50 kilodalton cytosolic protein
Lacy J, Bartiss A, Coleman D. Conversion of a human B cell lymphoma line by Epstein-Barr virus is associated with increased tyrosine phosphorylation of a 50 kilodalton cytosolic protein. Virus Research 1991, 20: 85-96. PMID: 1656626, DOI: 10.1016/0168-1702(91)90063-2.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusB cellsHuman B cellsB-cell lymphoma linePresence of EBVLymphoma linesProtein tyrosine phosphorylationEBV infectionHuman B cell lymphoma lineTyrosine phosphorylationB lymphocytesImmortalized lymphoblastoid cellsBiochemical changesLymphoblastoid cellsInfectionEndogenous tyrosine kinasesContinuous proliferationCytosolic proteinsTyrosine kinaseVirusCellsPhosphorylationPhosphotyrosine antibodiesLymphocytesProtein
1990
Macrophage colony-stimulating factor production by murine and human keratinocytes. Enhancement by bacterial lipopolysaccharide.
Chodakewitz J, Lacy J, Edwards S, Birchall N, Coleman D. Macrophage colony-stimulating factor production by murine and human keratinocytes. Enhancement by bacterial lipopolysaccharide. The Journal Of Immunology 1990, 144: 2190-6. PMID: 2179407, DOI: 10.4049/jimmunol.144.6.2190.Peer-Reviewed Original Research
1989
Rat mesangial cells produce granulocyte-macrophage colony-stimulating factor
Budde K, Coleman D, Lacy J, Sterzel R. Rat mesangial cells produce granulocyte-macrophage colony-stimulating factor. American Journal Of Physiology 1989, 257: f1065-f1078. PMID: 2690641, DOI: 10.1152/ajprenal.1989.257.6.f1065.Peer-Reviewed Original ResearchConceptsRat mesangial cellsGranulocyte-macrophage colony-stimulating factorCultured rat mesangial cellsMesangial cellsColony-stimulating factorGM-CSFMC-CMGlomerular mesangial cellsPeritoneal MPsEffector cellsIL-2Inflammatory processGlomerular diseaseInterleukin-2T cellsT lymphocytesInterleukin-4Murine GM-CSFRenal glomeruliSerum-free conditionsSoluble factorsProliferative activitySpecific cDNA probesGM-CSF mRNA transcriptsPresent findingsPost‐transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein‐Barr virus.
Lacy J, Summers W, Summers W. Post‐transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein‐Barr virus. The EMBO Journal 1989, 8: 1973-1980. PMID: 2551670, PMCID: PMC401064, DOI: 10.1002/j.1460-2075.1989.tb03603.x.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusB cell linesBJAB cellsNegative Burkitt lymphoma linesPresence of EBVLymphoma linesBurkitt lymphoma linesCell linesNormal human B cellsHuman B cell linesHuman B cellsMYC mRNAEBV genomeVitro infectionMyc transcriptsB cellsEBVLymphoblastoid linesMYC expressionVirusMechanism of deregulationCellsPost-transcriptional mechanismsMYC
1987
Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line.
Lacy J, Summers W, Watson M, Glazer P, Summers W. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Proceedings Of The National Academy Of Sciences Of The United States Of America 1987, 84: 5838-5842. PMID: 3039510, PMCID: PMC298958, DOI: 10.1073/pnas.84.16.5838.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaEBV infectionB cell linesEpstein-Barr virus infectionEBV-negative Burkitt lymphomasEBV-positive sublinesEpstein-Barr virusAmplification of MYCRole of EBVMYC expressionPositive Burkitt's lymphomaHuman B cell linesDeregulation of MYCVirus infectionVitro infectionInfectionEBVAltered expressionBJAB cellsMYC transcriptionVirusMYC oncogeneMYC locusMYCCells
1985
Effects of diacetyl diamines on in vitro activation and proliferation of human B lymphocytes.
Lacy J, Summers W, Canellakis Z. Effects of diacetyl diamines on in vitro activation and proliferation of human B lymphocytes. The Journal Of Immunology 1985, 135: 3772-6. PMID: 3877754, DOI: 10.4049/jimmunol.135.6.3772.Peer-Reviewed Original ResearchConceptsB cell activationHuman B lymphocytesB cellsHuman B cellsB lymphocytesCell activationGrowth factor-stimulated proliferationProliferation of PHAHuman B cell activationNormal B cellsHuman T cellsT cellsProliferative responseCowan IAntiproliferative effectsSpecific abrogationInhibitory effectLymphocytesActivationProliferationHexamethylenebisacetamideCellsDerivatives of polyaminesCulture mediumDose